Related Experiment Video

Updated: Jun 14, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive

Yongzheng Wang1, Xuwei Hou, Yuliang Li

  • 1Department of Interventional Radiology, The Second Hospital of Shandong University, Shangdong, PR China.

Journal of Biomedical Science
|April 2, 2010
PubMed

Insights

Transforming growth factor beta 1 (TGF-β1) gene polymorphisms are linked to atrial fibrillation (AF) in essential hypertension (EH). The +915 G --> C polymorphism at codon 25, specifically the GG genotype, increases AF risk and serum TGF-β1 levels in EH patients.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Hypertension Research

Background:

  • The relationship between transforming growth factor beta 1 (TGF-β1) gene polymorphisms and atrial fibrillation (AF) in essential hypertensive (EH) individuals is not well understood.
  • Essential hypertension is a significant risk factor for developing AF.
  • TGF-β1 plays a role in cardiac remodeling and fibrosis, processes implicated in AF pathogenesis.

Purpose of the Study:

  • To investigate the association between specific TGF-β1 gene polymorphisms and the occurrence of AF in subjects with essential hypertension.
  • To determine if these polymorphisms correlate with serum TGF-β1 levels in the study population.

Main Methods:

  • Genotyping of TGF-β1 polymorphisms at +869 T --> C (codon 10) and +915 G --> C (codon 25) was performed.
  • Essential hypertensive subjects with AF (EH+AF+) and without AF (EH+AF-) were enrolled.
  • Clinical characteristics and serum TGF-β1 levels were measured in all participants.

Main Results:

  • The GG genotype of the TGF-β1 +915 G --> C polymorphism at codon 25 was significantly more prevalent in the EH+AF+ group compared to the EH+AF- group (P = 0.009).
  • Subjects with the GG genotype in the EH+AF+ group exhibited higher mean serum TGF-β1 levels than those in the EH+AF- group (3.18 ± 0.24 ng/dl vs. 2.29 ± 0.14 ng/dl, P < 0.05).
  • Multivariate analysis indicated that the TGF-β1 GG genotype at +915 G --> C (codon 25) conferred a 3.09-fold increased risk of developing AF, even after adjusting for age and gender.

Conclusions:

  • Polymorphisms in the TGF-β1 gene, specifically the +915 G --> C variation at codon 25, are associated with the occurrence of AF in essential hypertensive subjects.
  • The GG genotype of this polymorphism is linked to elevated serum TGF-β1 levels and an increased risk of AF in this population.
Abstract

More Related Videos

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
TGF - &#946; Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Antihypertensive Drugs: Action of &#946;1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...